PLRX (Pliant Therapeutics, Inc.) Stock Financials & Earnings

PLRXPliant Therapeutics, Inc.

Mkt Cap$85M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$175M

EPS (TTM)-$2.88

Free Cash Flow (TTM)-$159M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q4 2025 · Mar 16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$2M	$912K	-$37M
Q1 23	$1M	$271K	-$42M
Q2 23	$248K	-$856K	-$47M
Q3 23	$0	$0	-$48M
Q4 23	$0	$0	-$47M
Q1 24	$0	-$513K	-$52M
Q2 24	$0	-$622K	-$61M
Q3 24	$0	$0	-$62M
Q4 24	$0	$0	-$53M
Q1 25	$0	$0	-$59M
Q2 25	$0	-$447K	-$46M
Q3 25	$0	$0	-$28M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$24M	—	$14M
Q1 23	$28M	—	$14M
Q2 23	$32M	—	$15M
Q3 23	$32M	$15M	—
Q4 23	$33M	$14M	—
Q1 24	$37M	$15M	—
Q2 24	$45M	$15M	—
Q3 24	$48M	$14M	—
Q4 24	$39M	$15M	—
Q1 25	$43M	$15M	—
Q2 25	$32M	$13M	—
Q3 25	$18M	$10M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$34M	$298M	$331M
Q1 23	$103M	$475M	$577M
Q2 23	$55M	$500M	$555M
Q3 23	$58M	$466M	$524M
Q4 23	$63M	$431M	$494M
Q1 24	$114M	$368M	$482M
Q2 24	$80M	$356M	$437M
Q3 24	$80M	$325M	$405M
Q4 24	$71M	$285M	$356M
Q1 25	$92M	$214M	$306M
Q2 25	$87M	$176M	$263M
Q3 25	$94M	$148M	$242M

Shares Outstanding

Revenue Per Employee

Revenue / Employee